Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Mar 27:10:293.
doi: 10.3389/fneur.2019.00293. eCollection 2019.

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Paul Lingor  1   2 , Markus Weber  3 , William Camu  4 , Tim Friede  5 , Reinhard Hilgers  5 , Andreas Leha  5 , Christoph Neuwirth  3 , René Günther  6   7 , Michael Benatar  8 , Magdalena Kuzma-Kozakiewicz  9 , Helen Bidner  10 , Christiane Blankenstein  10 , Roberto Frontini  11 , Albert Ludolph  12 , Jan C Koch  2 ; ROCK-ALS Investigators
Collaborators, Affiliations
Case Reports

ROCK-ALS: Protocol for a Randomized, Placebo-Controlled, Double-Blind Phase IIa Trial of Safety, Tolerability and Efficacy of the Rho Kinase (ROCK) Inhibitor Fasudil in Amyotrophic Lateral Sclerosis

Paul Lingor et al. Front Neurol. .

Abstract

Objectives: Disease-modifying therapies for amyotrophic lateral sclerosis (ALS) are still not satisfactory. The Rho kinase (ROCK) inhibitor fasudil has demonstrated beneficial effects in cell culture and animal models of ALS. For many years, fasudil has been approved in Japan for the treatment of vasospasm in patients with subarachnoid hemorrhage with a favorable safety profile. Here we describe a clinical trial protocol to repurpose fasudil as a disease-modifying therapy for ALS patients. Methods: ROCK-ALS is a multicenter, double-blind, randomized, placebo-controlled phase IIa trial of fasudil in ALS patients (EudraCT: 2017-003676-31, NCT: 03792490). Safety and tolerability are the primary endpoints. Efficacy is a secondary endpoint and will be assessed by the change in ALSFRS-R, ALSAQ-5, slow vital capacity (SVC), ECAS, and the motor unit number index (MUNIX), as well as survival. Efficacy measures will be assessed before (baseline) and immediately after the infusion therapy as well as on days 90 and 180. Patients will receive a daily dose of either 30 or 60 mg fasudil, or placebo in two intravenous applications for a total of 20 days. Regular assessments of safety will be performed throughout the treatment period, and in the follow-up period until day 180. Additionally, we will collect biological fluids to assess target engagement and evaluate potential biomarkers for disease progression. A total of 120 patients with probable or definite ALS (revised El Escorial criteria) and within 6-18 months of the onset of weakness shall be included in 16 centers in Germany, Switzerland and France. Results and conclusions: The ROCK-ALS trial is a phase IIa trial to evaluate the ROCK-inhibitor fasudil in early-stage ALS-patients that started patient recruitment in 2019.

Keywords: ROCK inhibition; amyotrophic lateral sclerosis; clinical trial protocol; disease-modification; study design.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scheme of trial (drawn to time scale). V, visit; bid, two times daily.
See this image and copyright information in PMC

References

    1. Koch J-C, Tatenhorst L, Roser AE, Saal KA, Tönges L, Lingor P. ROCK inhibition in models of neurodegeneration and its potential for clinical translation. Pharmacol Ther. (2018) 189(C):1–21. 10.1016/j.pharmthera.2018.03.008 - DOI - PubMed
    1. Dong M, Yan BP, Liao JK, Lam YY, Yip GW, Yu CM. Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases. Drug Discov Today. (2010) 15:622–9. 10.1016/j.drudis.2010.06.011 - DOI - PMC - PubMed
    1. Tönges L, Koch JC, Bähr M, Lingor P. ROCKing regeneration: rho kinase inhibition as molecular target for neurorestoration. Front Mol Neurosci. (2010) 4:39. 10.3389/fnmol.2011.00039 - DOI - PMC - PubMed
    1. Tönges L, Frank T, Tatenhorst L, Saal KA, Koch JC, Szego ÉM, et al. . Inhibition of rho kinase enhances survival of dopaminergic neurons and attenuates axonal loss in a mouse model of Parkinson's disease. Brain. (2012) 135(Pt 11):3355–70. 10.1093/brain/aws254 - DOI - PMC - PubMed
    1. Takata M, Tanaka H, Kimura M, Nagahara Y, Tanaka K, Kawasaki K, et al. . Fasudil, a rho kinase inhibitor, limits motor neuron loss in experimental models of amyotrophic lateral sclerosis. Br J Pharmacol. (2013) 170:341–51. 10.1111/bph.12277 - DOI - PMC - PubMed

Publication types